20064-19-1
Chemical Structure
Propionyl-L-carnitine
- CAS No.: 20064-19-1
- Formula:C10H19NO4
- Molecular Weight:217.26
IUPAC Name: (R)-3-(propionyloxy)-4-(trimethylammonio)butanoate
InChIKey: UFAHZIUFPNSHSL-MRVPVSSYSA-N
SMILES: CCC(O[C@@H](C[N+](C)(C)C)CC([O-])=O)=O
Biological Activity: Propionyl-L-carnitine is an orally active L-carnitine derivative. Propionyl-L-carnitine has a high affinity for muscle L-carnitine transferase. Propionyl-L-carnitine increases Apoptosis, Bax, and reduces NF-κB, VCAM-1, MCP-1, and survivin. Propionyl-L-carnitine activates Src kinase, Akt, induces p-AMPK and nitric oxide synthesis. Propionyl-L-carnitine alleviates cardiovascular disease, obesity, and colitis[1][2][3][4][5][6][7][8][9][10].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Propionyl-L-carnitine | 95.0% | Propionyl-L-carnitine is an orally active L-carnitine derivative. Propionyl-L-carnitine has a high affinity for muscle L-carnitine transferase. Propionyl-L-carnitine increases Apoptosis, Bax, and reduces NF-κB, VCAM-1, MCP-1, and survivin. Propionyl-L-carnitine activates Src kinase, Akt, induces p-AMPK and nitric oxide synthesis. Propionyl-L-carnitine alleviates cardiovascular disease, obesity, and colitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Victor Kamoen, et al. Propionyl-L-carnitine for intermittent claudication. Cochrane Database Syst Rev. 2021 Dec 26;12(12):CD010117. [Content Brief]
- [2]. Ning WH, et al. Propionyl-L-carnitine induces eNOS activation and nitric oxide synthesis in endothelial cells via PI3 and Akt kinases. Vascul Pharmacol. 2013 Sep-Oct;59(3-4):76-82. [Content Brief]
- [3]. Orlandi A, et al. Propionyl-L-carnitine reduces proliferation and potentiates Bax-related apoptosis of aortic intimal smooth muscle cells by modulating nuclear factor-kappaB activity. J Biol Chem. 2007 Feb 16;282(7):4932-4942. [Content Brief]
- [4]. Scioli MG, et al. Propionyl-L-Carnitine Enhances Wound Healing and Counteracts Microvascular Endothelial Cell Dysfunction. PLoS One. 2015 Oct 16;10(10):e0140697. [Content Brief]
- [5]. Mister M, et al. Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidney Int. 2002 Mar;61(3):1064-78. [Content Brief]
- [6]. Mingorance C, et al. Propionyl-L-carnitine corrects metabolic and cardiovascular alterations in diet-induced obese mice and improves liver respiratory chain activity. PLoS One. 2012;7(3):e34268. [Content Brief]
- [7]. Scioli MG, et al. Propionyl-L-Carnitine is Efficacious in Ulcerative Colitis Through its Action on the Immune Function and Microvasculature. Clin Transl Gastroenterol. 2014 Mar 20;5(3):e55. [Content Brief]
- [8]. Alvarez de Sotomayor M, et al. Effect of L-carnitine and propionyl-L-carnitine on endothelial function of small mesenteric arteries from SHR. J Vasc Res. 2007;44(5):354-64. [Content Brief]
- [9]. Al-Majed AA, et al. Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res. 2006 Mar;53(3):278-86. [Content Brief]
- [10]. Mingorance C, et al. Oral supplementation of propionyl-l-carnitine reduces body weight and hyperinsulinaemia in obese Zucker rats. Br J Nutr. 2009 Oct;102(8):1145-53. [Content Brief]
